# Nektar Therapeutics

Source: https://onco.cc/companies/nektar-therapeutics/  
OnCo record `nektar-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Nektar is a San Francisco biotechnology company whose polymer conjugation chemistry underlies several approved drugs and whose engineered interleukin-2, bempegaldesleukin, failed in phase 3 with nivolumab in 2022.

## Summary

Nektar Therapeutics, listed on Nasdaq, built its business on PEGylation and polymer conjugate chemistry licensed into products such as pegfilgrastim-type molecules and movantik. Its own oncology bet, bempegaldesleukin (NKTR-214), a PEGylated interleukin-2 designed to favour effector T cells, was developed with Bristol Myers Squibb in a large phase 3 programme with nivolumab that reported negative results in melanoma, renal cell carcinoma and bladder cancer in 2022, after which the programme was closed. OnCo records it as a registry sponsor of phase 3 cancer trials.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Nektar
- Tags: ctgov-sponsor
- HQ: San Francisco, CA
- Type: biotech
- Website: https://www.nektar.com

## Sources

- Official website: https://www.nektar.com
- ClinicalTrials.gov: trials led by Nektar Therapeutics: https://clinicaltrials.gov/search?lead=Nektar%20Therapeutics
- Wikipedia: https://en.wikipedia.org/wiki/Nektar_Therapeutics

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Melanoma](https://onco.cc/cancers/melanoma/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- drugs: [Bempegaldesleukin](https://onco.cc/drugs/bempegaldesleukin/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)

---
JSON: https://onco.cc/api/v1/entities/nektar-therapeutics.json